BiomEdit
Fishers
About BiomEdit
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of the microbiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $68.9M
- Funding stage: Early Stage Venture
- Last round: Grant (Oct 2025)
- Website: biomedit.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/biomedit-25551 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.